Everything below concerns GHRH analogue. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-27. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
López-Muñoz, F.; Ucha-Udabe, R.; Alamo, C. (2005). "The history of barbiturates a century after their clinical introduction". Neuropsychiatric Disease and Treatment. 1 (4): 329–343. PMC 2424120. PMID 18568113.
== History == Inotuzumab ozogamicin was discovered by scientists collaborating at Celltech and Wyeth, and it was developed by Pfizer which had acquired Wyeth. Celltech and Wyeth entered into a collaboration in 1991 to develop antibody-drug conjugates. The humanized antibody portion was generated at Celltech and the DNA encoding it was transfected into CHO cells, which were sent to Wyeth, where chemists expressed and purified the antibodies and conjugated them with the linker to the cytotoxin; the work was published in 2004. Celltech was acquired by UCB in 2004 and Wyeth was acquired by Pfizer in 2009. In May 2013, a phase III trial in participants with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL) who were not candidates for intensive high-dose chemotherapy was terminated for futility. In March 2024, the FDA approved inotuzumab ozogamicin for the treatment of children aged one year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia. Efficacy was evaluated in a multicenter, single-arm, open-label study in 53 pediatric participants aged one year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia. Two dose levels were evaluated--an initial dose of 1.4 mg/m2/cycle in 12 participants and 1.8 mg/m2/cycle in 41 participants. Premedications included methylprednisolone 1 mg/kg (maximum of 50 mg), an antipyretic, and an antihistamine. Participants received a median of 2 cycles of therapy (range: 1 to 4 cycles).
These N-methyltryptamines are much more lipophilic than serotonin and, in contrast, are able to diffuse into serotonergic neurons and activate intracellular serotonin 5-HT2A receptors. Another metabolite of serotonin with possible psychedelic-like effects in animals is 5-methoxytryptamine (5-MT). DMT is a naturally occurring endogenous compound in the body. In relation to the fact that serotonin itself is unable to activate intracellular serotonin 5-HT2A receptors, it is possible that DMT might be the endogenous ligand of these receptors rather than serotonin.
Clytia hemisphaerica is a small hydrozoan-group cnidarian, about 1 cm in diameter, that is found in the Mediterranean Sea and the North-East Atlantic Ocean. Clytia has the free-swimming jellyfish form typical of the Hydrozoa, as well as vegetatively propagating polyps. Clytia hemisphaerica has emerged as a promising model organism as its life cycle, small size, and relatively easy upkeep make it conducive to experimental manipulation and maintenance in a laboratory setting. Some examples of studies already conducted in Clytia include those looking at embryonic development, differential patterns of gene expression during life stages, and wound healing. Clytia's genome was sequenced in full in March 2019.
Sources: en.wikipedia.org
By late April, the Trump administration had placed on leave and then temporarily rehired federal employees in the NIOSH, or National Institute of Occupational Safety and Health, who had been involved in monitoring for black lung disease. On June 9, Kennedy fired all 17 members of the Advisory Committee for Immunization Practices. He claimed that it "has become little more than a rubber stamp for any vaccine". Senator Bill Cassidy, a medical doctor, said "now the fear is that the ACIP will be filled up with people who know nothing about vaccines except suspicion." These firings came before a scheduled June 25 meeting in which the committee was expected to issue new recommendations for vaccines including COVID-19.
In October 2025, GSK announced it had acquired the rights to a prostate cancer drug developed by Syndivia, a French biotechnology company, for £268 million. In January 2026, GSK agreed to acquire Rapt Therapeutics in a deal valued at $2.2 billion. In January 2026, Alteogen Inc. entered into an exclusive license agreement with Tesaro, Inc., a subsidiary of GSK, allowing Tesaro to acquire world-wide rights to use ALT-B4, Alteogen's novel hyaluronidase utilising Hybrozyme technology, for the development and commercialisation of a subcutaneous formulation of dostarlimab, a programmed death receptor-1 (PD-1) blocking antibody. In February 2026, GlaxoSmithKline announced an agreement to acquire Canada-based biopharmaceutical firm 35Pharma for $950 million in cash. The deal includes the early-stage drug HS235 for pulmonary arterial hypertension and related conditions. In June 2026, GSK announced it was acquiring Nuvalent, an American biopharmaceutical company, for $10.6 billion. Subject to regulatory and shareholder approval, if complete, the deal will be its largest in more than 10 years.
====== LAESI ====== In Laser ablation electrospray ionization (LAESI), a laser is used to ablate the surface of the sample and the emitted molecules are ionized in the gas phase by charged droplets from electrospray. Similar to DESI the ionization happens in ambient conditions. Anderton et al. used this ionization technique coupled to a Fourier transform mass spectrometer to analyze 200 single cells of Allium cepa (red onion) with high spatial resolution.
Sulfanilamide (also spelled sulphanilamide) is a sulfonamide antibacterial drug. Chemically, it is an organic compound consisting of an aniline derivatized with a sulfonamide group. Powdered sulfanilamide was used by the Allies in World War II to reduce infection rates and contributed to a dramatic reduction in mortality rates compared to previous wars. Sulfanilamide is rarely if ever used systemically due to toxicity and because more effective sulfonamides are available for this purpose. Modern antibiotics have supplanted sulfanilamide on the battlefield; however, sulfanilamide remains in use today in the form of topical preparations, primarily for treatment of vaginal yeast infections such as vulvovaginitis caused by Candida albicans. The term "sulfanilamides" is also sometimes used to describe a family of molecules containing these functional groups. Examples include:
=== Organizations === In response to Verification for Organizations, various news organizations—including The New York Times, Los Angeles Times, The Washington Post, BuzzFeed News, HuffPost, Politico, and Vox Media sites—stated that they would not pay for Twitter verification for their employees. CNN said that it would not pay for employee verification status except for some staff members. The White House has no intentions to pay for checkmarks for their employees, according to Axios. The Twitter account for Amazon Prime Video in the United Kingdom posted a meme of The Boys character Homelander pushing his son off a roof, with Homelander labeled as Twitter and his son labeled as a blue checkmark. Law blog SCOTUSblog stopped posting on Twitter entirely after it lost its checkmark.
Sources: en.wikipedia.org
A new Hardee's logo was unveiled in 2006 that featured script lettering and retained the iconic Happy Star, further unifying the Hardee's and Carl's Jr. brands. Hardee's also marketed special Super Bowl celebratory pins in the early 1990s.
The introduction of Di(2-propylheptyl) phthalate (DPHP) was driven by increasing regulatory scrutiny and health concerns associated with traditional plasticizers. DPHP was developed to meet the demand for plasticizers with improved safety profiles, particularly in applications involving human contact. As a result of its production through the esterification of phthalic anhydride with 2-propylheptanol, it results in a compound with low volatility and high thermal stability, making it suitable for various applications, including automotive interiors, wire and cable insulation, and flooring materials. The compound gained regulatory attention in the European Union, where it was included in the Community Rolling Action Plan (CoRAP) under the REACH regulation in 2014. This inclusion was due to concerns about its widespread use, potential endocrine-disrupting properties, and exposure risks to sensitive populations. Germany was tasked with evaluating DPHP's health and environmental impacts, with the assessment process beginning in 2020. Research into DPHP's metabolism and exposure markers has been conducted to better understand its behavior in biological systems. A 2019 study utilized ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) in a rat model to identify potential biomarkers for DPHP exposure, aiding in the assessment of human exposure levels.
=== Story === For the first year of development, the team focused mostly on the gameplay without narrative structure. Playtesters found the game fun but asked about what these test chambers were leading towards. This prompted the team to come up with a narrative for Portal. The team worked with Marc Laidlaw, the writer of the Valve's Half-Life series, to fit Portal into the Half-Life universe. This was done in part because of the project's limited art resources; instead of creating art assets for Portal, the team reused the Half-Life 2 assets. Laidlaw opposed the crossover, feeling it "made both universes smaller", and said later: "I just had to react as gracefully as I could to the fact that it was going there without me. It didn't make any sense except from a resource-restricted point of view." Valve hired Erik Wolpaw and Chet Faliszek to write Portal. Wolpaw felt that the constraints improved the game. The concept of a computer AI guiding the player through experimental facilities to test the portal gun was arrived at early in the writing process. They drafted early lines for a "polite" AI with humorous situations, such as requesting the player's character to "assume the party escort submission position", and found this style of approach to be well-suited to the game they wanted to create, leading to the creation of the GLaDOS character. GLaDOS was central to the plot.
=== Batch reactor === Batch reactors are reactors in which the reactants are put in the reactor at time 0 and react until the reaction is stopped. Consequently, the space time is the same as the average residence time in a batch reactor.
He previously worked as an analyst with the International Crisis Group.; co-founder of J Street and has served on the organization's advisory council; also a founding board member of Molad: The Center for the Renewal of Israeli Democracy as well as the Diaspora Alliance; serves on board of New Israel Fund and as trustee of Rockefeller Brothers Fund; editor with Foreign Policy magazine as editor of their Middle East Channel He publishes and speaks widely on matters related to Israel and Palestine.; has appeared on and written for The Nation, The New York Times, Ha'aretz, the BBC, Al Jazeera, and CNN. Eylon Levy (born London, 1991) is an official Israeli government spokesman, serving since the start of Gaza war. He served previously as international media advisor to President Isaac Herzog, after a career as a television news anchor at i24News and IBA News. Levy's work has appeared in Newsweek, Jerusalem Post, Times of Israel, The Daily Caller, Arutz Sheva/Israel National News, Tablet Magazine, The Washington Post, The Guardian, and The Daily Telegraph. Martin Lewis (financial journalist) (born 9 May 1972) financial journalist and broadcaster, has worked for BBC, Channel 5 (British TV channel), ITV's This Morning (TV programme) and written for The Sunday Post, The Yorkshire Post, the Manchester Evening News, Express & Star, has been a columnist for The Sunday Times, News of the World, The Guardian and the Sunday Express. Tim Lott(born 23 January 1956); author and journalist for The Guardian.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
Lyophilized material is typically kept refrigerated and away from light in the sealed vial provided. Dissolved material is generally used within a limited period rather than stored long term.